Abstract:Resistance to praziquantel (PZQ) for S. japonicum was induced to evaluate whether there is cross resistance to the PZQ derivative DW-3-15 for PZQ-resistant adult worms of S. japonicum. The mice infected with S. japonicum were given subcurative (effective dose required to kill 50% of the worms, ED50) PZQ orally on the 21st day after infection, for 30 consecutive days. Then with 21 days interval mice were treated again with curative (200 mg/kg) PZQ for 5 successive days. Two weeks post-treatment, in vitro, we observed that the critical lethal concentration (the lowest dose required to make 72 h vitality reduction reach to 90%) of PZQ against adult worms induced was eight times as high as uninducible worms, while the critical lethal concentration of DW-3-15 against PZQ-resistant adult worms was the same as that of the uninducible. The data revealed that PZQ-resistant adult worms showed no cross resistance to DW-3-15. These results indicate that the targets of PZQ and DW-3-15 against S. japonicum may be different. DW-3-15 will perhaps be a potentially novel drug for treatment of schistosomiasis.
[1] Kasinathan RS, Sharma LK, Cunningham C, et al. Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to praziquantel[J]. PLoS Neglect Trop D, 2014, 8(10): e3265. [2] Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade[J]. PLoS Neglect Trop D, 2009, 3(9): e485. [3] King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis[J]. Chronic Illness, 2008, 4(1): 65-79. [4] van der Werf MJ, de Vlas SJ, Brooker S, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa[J]. Acta Trop, 2003, 86(2): 125-139. [5] Xiao SH. Progress in development of new antischistosomal drugs in recent years[J]. Chin J Parasitol Parasit Dis, 2010, 28(3): 218-225. (in Chinese) 肖树华. 近年来发展抗血吸虫新药的进展[J].中国寄生虫学与寄生虫病杂志, 2010, 28(3):218-225. [6] Toure S, Zhang Y, Bosque-Oliva E, et al. Two-year impact of single praziquantel treatment on infection in the national control programme on schistosomiasis in Burkina Faso[J]. B World Health Organ, 2008, 86(10): 780-787A. [7] Vennervald BJ, Booth M, Butterworth AE, et al. Regression of hepatosplenomegaly in Kenyan school-aged children after praziquantel treatment and three years of greatly reduced exposure to Schistosoma mansoni[J]. T Roy Soc Trop Med H, 2005, 99(2): 150-160. [8] Hagan P, Appleton CC, Coles GC, et al. Schistosomiasis control: keep taking the tablets[J]. Trends Parasitol, 2004, 20(2): 92-97. [9] Fenwick A, Savioli L, Engels D, et al. Drugs for the control of parasitic diseases: current status and development in schistosomiasis[J]. Trends Parasitol, 2003, 19(11): 509-515. [10] Caffrey CR. Chemotherapy of schistosomiasis: present and future[J]. Curr Opin Chem Biol, 2007, 11(4): 433-439. [11] Abdul-Ghani RA, Loutfy N, Hassan A. Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use[J]. Parasitol Res, 2009, 105(4): 899-906. [12] Dong LL, Xu J, Zhao B, et al. Drug resistance induction and analysis of differential expression protein on adult Schistosoma japonicum induced by ED 50 PZQ[J]. Chin J Zoonoses, 2014, 30(12): 1171-1180. (in Chinese) 董兰兰, 许静, 赵波, 等. 吡喹酮压力下日本血吸虫耐药性的诱导和虫体差异表达蛋白的分析[J].中国人兽共患病学报, 2014, 30(12): 49-58. [13] Pica-Mattoccia L, Valle C, Basso A, et al. Cytochalasin D abolishes the schistosomicidal activity of praziquantel[J]. Exp parasitol, 2007, 115(4): 344-351. [14] Vanaerschot M, Huijben S, Van den Broeck F, et al. Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race[J]. FEMS Microbiol Rev, 2014, 38(1): 41-55. [15] Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific[J]. Am J Trop Med Hyg, 1994, 51: 83-88. [16] Stelma FF, Talla I, Sow S, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni [J]. Am J Trop Med Hyg, 1995, 53(2): 167-170. [17] Ismail M, Metwally A, Farghaly A, et al. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel[J]. Am J Trop Med Hyg, 1996, 55(2): 214-218. [18] Coles GC, Kinoti GK. Defining resistance in Schistosoma [J]. Parasitol Today, 1997, 13(4): 157-158. [19] Couto FFB, Coelho PMZ, Araujo N, et al. Schistosoma mansoni : a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails[J]. Mem Inst Oswaldo Cruz, Rio de Janeiro, 2011, 106(2): 153-157. [20] Yang QL, Cai R, Li X, et al. Selected schistosomes of decreased praziquantel sensitivity and ultranstructural alterations of worms under drug pressure[J]. Chin J Schisto Ctrl, 2010, 22(3): 206-212. (in Chinese) 杨巧林, 蔡茹, 李欣, 等. 日本血吸虫吡喹酮耐药虫体筛选及其超微结构观察[J]. 中国血吸虫病防治杂志, 2010, 22(3):206-212. [21] Ru WW, Liang YS, Dai JR, et al. Studies on effect of artesunate against Schistosoma japonicum ⅠSusceptibility of different developed stages of worms in mice to artesunate[J]. Chin J Schisto Ctrl, 1996, 18(3): 161-164. (in Chinese) 茹炜炜, 梁幼生, 戴建荣, 等. 青蒿琥酯对日本血吸虫作用的研究.Ⅰ小鼠体内不同发育阶段虫体对青蒿琥酯的敏感性[J]. 中国血吸虫病防治杂志, 1996, 18(3): 161-164. [22] Colley DG, Bustinduy AL, Secor WE, et al. Human schistosomiasis[J]. Lancet, 2014, 383(9936): 2253-2264. [23] Duan WW, Qiu SJ, Zhao Y, et al. Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum [J]. Bioorg Med Chem Lett, 2012, 22(4): 1587-1590. [24] Dong LL, Duan WW, Chen JL, et al. An artemisinin derivative of praziquantel as an orally active antischistosomal agent[J]. PLoS One, 2014, 9(11): e112163.